Moreover, we previously reported that inhibiting Bcr-Abl and VEGF significantly attenuates LPS- or Aβ-mediated neuroinflammation, Aβ/tau pathology, or cognitive impairment in wild-type mice and an AD mouse model [5–7]. This evidence concerns the gene MAPT and Alzheimer disease.